title: Comparison of vascular leak syndrome in mice treated with IL21 or IL2.
abstract: Interleukin 21 (IL21) is a T-cell-derived 4-helix-bundle cytokine that has sequence homology to the IL2 family. Recombinant human interleukin 2 (rIL2) is approved for the treatment of metastatic melanoma and renal cell carcinoma. However, toxicity of rIL2, including induction of vascular leak syndrome (VLS), has limited use of this cytokine to a small proportion of eligible patients. Both rIL2 and murine IL21 (mIL21) have potent antitumor efficacy in murine models. The purpose of the current study was to compare the ability of mIL21 and rIL2 to induce vascular leakage in a mouse model. Pulmonary and hepatic uptake of Evans blue dye, serum cytokine levels, spleen cell immunophenotype, and histologic changes in lung and liver were evaluated to detect VLS. High-dose (200 μg) rIL2 treatment induced vascular leakage in mice, evidenced by inflammatory cell infiltration and fluid extravasation into the lung and liver and increased levels of TNFα, IFNγ, IL5, MCP1, and IL6 in serum. In contrast, an equivalent dose of mIL21 resulted in minimal vascular leakage with no evidence of cytopenia or cytokine production. These results support the use of IL21 as a cancer immunotherapeutic agent, potentially providing an antitumor response without induction of VLS.
authors.affiliation: ZymoGenetics, a Bristol-Myers Squibb Company, Seattle, Washington, USA.
authors.forename: Pallavur V
authors.initials: PV
authors.lastname: Sivakumar
authors.forename: Richard
authors.initials: R
authors.lastname: Garcia
authors.forename: Kimberly S
authors.initials: KS
authors.lastname: Waggie
authors.forename: Monica
authors.initials: M
authors.lastname: Anderson-Haley
authors.forename: Andrew
authors.initials: A
authors.lastname: Nelson
authors.forename: Steven D
authors.initials: SD
authors.lastname: Hughes
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D019559:Capillary Leak Syndrome / Q000139:chemically induced* / Q000473:pathology; D016207:Cytokines / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005070:Evans Blue; D006801:Humans; D016130:Immunophenotyping; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods*; D007376:Interleukin-2 / Q000009:adverse effects*; D007378:Interleukins / Q000009:adverse effects*; D008099:Liver / Q000378:metabolism / Q000473:pathology; D008168:Lung / Q000378:metabolism / Q000473:pathology; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D011994:Recombinant Proteins / Q000009:adverse effects*; D000098546:Interleukin-21
chemical_list: D016207:Cytokines; D007376:Interleukin-2; D007378:Interleukins; D011994:Recombinant Proteins; D005070:Evans Blue; D000098546:Interleukin-21
references.citation: J Immunol. 2007 Mar 1;178(5):2827-34
references.pmid: 17312126
references.citation: Cancer J. 2008 Sep-Oct;14(5):320-4
references.pmid: 18836337
references.citation: Drug Saf. 1992 Nov-Dec;7(6):417-33
references.pmid: 1418698
references.citation: J Immunol. 2004 Dec 15;173(12):7521-30
references.pmid: 15585879
references.citation: Cancer Immunol Immunother. 2009 Jun;58(6):843-54
references.pmid: 18925392
references.citation: J Clin Invest. 1996 Apr 15;97(8):1952-9
references.pmid: 8621780
references.citation: J Immunol. 2004 Feb 15;172(4):2048-58
references.pmid: 14764669
references.citation: J Immunol. 1988 Jul 1;141(1):189-200
references.pmid: 3259967
references.citation: J Immunother. 2008 Jul-Aug;31(6):569-76
references.pmid: 18528297
references.citation: J Immunol. 2004 Jul 15;173(2):900-9
references.pmid: 15240677
references.citation: Immunity. 2002 Apr;16(4):559-69
references.pmid: 11970879
references.citation: J Immunol. 2005 Dec 15;175(12):7867-79
references.pmid: 16339522
references.citation: J Clin Oncol. 2008 Apr 20;26(12):2034-9
references.pmid: 18347008
references.citation: J Exp Med. 1989 Jan 1;169(1):161-73
references.pmid: 2783332
references.citation: Cell Immunol. 1994 Aug;157(1):170-80
references.pmid: 8039244
references.citation: Methods Cell Biol. 1994;43 Pt A:161-89
references.pmid: 7823861
references.citation: Cancer Immunol Immunother. 2007 Sep;56(9):1417-28
references.pmid: 17285290
references.citation: Lab Invest. 1988 Nov;59(5):598-612
references.pmid: 3263543
references.citation: Immunopharmacology. 1997 Oct;37(2-3):117-32
references.pmid: 9403331
references.citation: Cancer Immunol Immunother. 1999 Jan;47(5):243-8
references.pmid: 10022467
references.citation: Nature. 2000 Nov 2;408(6808):57-63
references.pmid: 11081504
references.citation: J Immunol. 2004 Nov 1;173(9):5361-71
references.pmid: 15494482
references.citation: Med Oncol. 2009;26 Suppl 1:3-12
references.pmid: 19148593
references.citation: Int J Toxicol. 2012 Jul-Aug;31(4):303-16
references.pmid: 22723515
references.citation: Expert Opin Biol Ther. 2008 Oct;8(10):1495-505
references.pmid: 18774918
references.citation: Clin Cancer Res. 2007 Jun 15;13(12):3630-6
references.pmid: 17575227
references.citation: J Immunol. 1999 Aug 1;163(3):1619-27
references.pmid: 10415067
references.citation: Int Rev Exp Pathol. 1993;34 Pt A:37-55
references.pmid: 8454416
references.citation: Mol Immunol. 2009 Feb;46(5):812-20
references.pmid: 18947877
references.citation: Oncology (Williston Park). 2002 Nov;16(11 Suppl 13):11-20
references.pmid: 12469935
references.citation: Clin Cancer Res. 2009 Mar 15;15(6):2123-9
references.pmid: 19276257
references.citation: Curr Oncol. 2007 Feb;14(1):21-6
references.pmid: 17576460
references.citation: Annu Rev Immunol. 2008;26:57-79
references.pmid: 17953510
references.citation: Clin Cancer Res. 2007 Dec 1;13(23):6926-32
references.pmid: 18056166
references.citation: J Immunol. 2001 Jul 1;167(1):1-5
references.pmid: 11418623
references.citation: J Immunol. 1986 Sep 1;137(5):1735-42
references.pmid: 3528289
references.citation: Cancer. 1991 Nov 15;68(10):2169-74
references.pmid: 1913455